Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluphenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.98 |
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 1.00 |
| ▸ | USP2 | O75604 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | RAD52 | P43351 | 4/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 3/20 | 1.00 |
| ▸ | GMNN | O75496 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | UBE2N | P61088 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluphenazine SCHEMBL2560022 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL1496274 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL29860638 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL41635 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL41634 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL7194249 | 0.99 | LMNA (0.98) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL29354183 | 0.99 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL5072860 | 0.99 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL29388890 | 0.99 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL19221 | 0.99 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20240145031-A1 | Methods and devices for drug repositioning and drug repurposing as nuclear receptor modulators | Precision Medicine Lab (NL) | 2024-05-02 | — | — | US | disclosed |
| US-20230218639-A1 | USE OF OXYGENATED CHOLESTEROL SULFATES FOR TREATING NEUROLOGICAL CONDITIONS, NEURODEGENERATIVE DISEASES, AND ADDICTION | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2023-07-13 | — | — | US | disclosed |
| EP-4171573-A1 | USE OF OXYGENATED CHOLESTEROL SULFATES FOR TREATING NEUROLOGICAL CONDITIONS, NEURODEGENERATIVE DISEASES, AND ADDICTION | Durect Corporation (US) | 2023-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218639-A1 | USE OF OXYGENATED CHOLESTEROL SULFATES FOR TREATING NEUROLOGICAL CONDITIONS, NEURODEGENERATIVE DISEASES, AND ADDICTION | CYP27A1, HSD3B2, HSD17B13 | DRD2 145/4885LMNA 3057/4885MAPT 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.